The efficacy and tolerability of amtolmetin guacyl (AMG), a new non-steroidal anti-inflammatory drug, were compared with piroxicam, in patients with osteoarthritis. In a randomized double-blind study patients with arthritis (n = 99) received either 600 mg AMG on an empty stomach or 20 mg of piroxicam on a full stomach, once daily for 30 days. All clinical parameters improved significantly with both drugs; there were no significant differences between the two treatments. Tolerability, assessed by the patients, was significantly better in the AMG group. In the piroxicam group nine of 50 patients withdrew because of side-effects (gastrointestinal) compared with two of 49 (nausea and headache) in the AMG group. There were three cases of perforation, ulcer and bleeding in the piroxicam group but no serious side-effects with AMG. Total numbers of sideeffects were similar in the two groups, but epigastric and abdominal pain were more frequent and more intense with piroxicam. AMG was as effective as piroxicam in controlling the symptoms of osteoarthritis, but showed better gastrointestinal tolerability.
INTRODUCTION
Osteoarthritis is the most widespread rheumatic pathology of the present day and is frequently the cause of invalidity. 1, 2 Despite the social impact of this disease, both in terms of reduced quality of life and cost, 3, 4 there is no valid existing therapy that can slow down the course of osteoarthritis or modify its natural history.
Non-steroidal anti-inflammatory drugs (NSAIDs) are still the drugs most used to reduce pain and improve articular use but they produce serious and numerous sideeffects, especially on the gastrointestinal system. 5 -7 The seriousness and frequency of these side-effects limits the use of NSAIDs and jeopardizes their therapeutic role. 8 -10 Gastric protection with misoprostol, H 2antagonists or proton pump inhibitors is not effective in all patients, may present sideeffects, is very expensive, and the real cost-effect relationship is still unclear. 11, 12 Research into NSAIDs with reduced toxicity is, therefore, a very high priority.
Amtolmetin guacyl (AMG) (Fig. 1) is a new NSAID that, in preliminary studies, has proved effective and shown good gastrointestinal tolerability. 13 -15 This drug derives clinically from the fusion between tolmetin with guaiacol and glycine, and is hydrolysed into two active metabolites: MED 5 and tolmetin. Animal studies both in vivo and in vitro indicate that, unlike its metabolites, this molecule does not induce gastric mucosal damage. 16 AMG is not selective for cyclo-oxygenase 2 (COX-2) and cannot be considered a nitric oxide (NO)-NSAID, although in the rat it induced a significant increase in NO synthase type-2 activity (NOS 2) while its metabolites were ineffective. 16, 17 A recent controlled clinical and gastroscopic trial, in patients suffering from rheumatoid arthritis, demonstrated the excellent gastric tolerability of AMG, which was decidedly superior to that of diclofenac, the comparator drug. 18 There are, so far, few studies of the treatment of osteoarthritis with AMG. The present study was designed to evaluate the effectiveness and tolerability of AMG in osteoarthritis, compared with piroxicam.
PATIENTS AND METHODS

PATIENTS
Patients with active symptomatic arthritis of the hips, knees, hands and spinal column, who were over 18 years of age, were enrolled (n = 100). Only those presenting with pain during active movement rated above 3.5 cm on a 10cm visual analogue scale (VAS) were enrolled.
The diagnosis of osteoarthritis was made on clinical grounds; radiological confirmation was requested only for arthritis of the spinal column. When patients presented with more than one site of pain, the most painful site was used to evaluate clinical parameters.
Patients with acute and chronic gastrointestinal pathologies were excluded, as well as those with serious liver, heart and kidney diseases, asthma, diabetes, epilepsy and allergy to NSAIDs or analgesics.
The local ethics committees approved the protocol and all patients gave their written informed consent.
STUDY DESIGN AND TREATMENT
This trial was carried out in three Italian centres under double-blind conditions. All patients underwent a washout period during which they did not use anti-inflammatory therapy for a variable period of 3 -7 days, depending on the half-life of the NSAID used previously.
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600 mg once a day on an empty stomach plus piroxicam placebo on a full stomach, or piroxicam 20 mg once a day on a full stomach plus AMG placebo on an empty stomach. AMG was administered on an empty stomach because, in animals, food seemed to reduce the contact between AMG and the gastric mucosa and thus the production of NO synthase 2 (unpublished data). Therapy continued for 30 days. During the study, the administration of anticoagulants, analgesics, other NSAIDs, gastroprotectors of any kind and antihistamines was forbidden.
ASSESSMENTS
The following clinical parameters were assessed at baseline and at the end of the trial: pain on active movement, pain at rest, patient's global assessment of disease activity (VAS). At the end of the trial, we also recorded the physician's global assessment of efficacy, and both the patient's and the physician's global assessments of tolerability (VAS). Standard laboratory tests were done at baseline and at the end of the trial. All sideeffects were registered and classified on Molecular structure of amtolmetin guacyl and its metabolites MED 5 and tolmetin. 
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the basis of their causal relationship with the drug under study. Compliance was evaluated by counting the remaining pills; patients with low compliance (who had not taken at least 60% of the pills) were excluded from the trial.
STATISTICAL ANALYSIS
All basal values were analysed to test homogeneity either between treatment groups or among centres. In particular, continuous data were analysed according to a two-factor analysis of variance, while discrete data reported as two by two frequency tables were analysed according to the Mantel-Haenszel test. Two-way (RxC) frequency tables were tested according to the χ 2 test, and frequency tables with more than two variables were analysed according to log-linear models. Equivalence analysis was performed on the variable voluntary pain at rest, which was used for sample size calculation and measured as VAS. Mean values were tested according to Schuirmann's Two One-Sided Test.
Pain on movement and the global evaluation of the course of the illness, both measured as VAS, were analysed with Schuirmann's Two One-Sided Test, bearing in mind that study hypothesis and sample size were defined on voluntary pain.
Efficacy parameters, measured as VAS, were analysed according to a two-factor (treatment and centre) analysis of variance with repeated measurements in order to assess any possible difference in treatment effect between centres. Patient and physician global efficacy judgement was analysed according to the linear trend test. Moreover, transforming clinical judgement as a dichotomized variable, a check for homogeneity among centres on this new variable was performed according to the Mantel-Haenszel test.
The frequency of side-effects during the trial period was analysed according to the Mantel-Haenszel test.
Laboratory examination was evaluated using two-factor analysis of variance with repeated measurements in order to detect possible difference between treatment effect and between centres.
The same laboratory results, reported as in-range (normal) or out-of-range (abnormal), were analysed according to the McNemar test within groups and according to the χ 2 test between groups.
RESULTS
Of the 100 patients enrolled in the trial, one was excluded for protocol violation. Therefore, the statistical analysis was carried out on 99 patients (49 in the AMG group and 50 in the piroxicam group). There were no significant differences in baseline characteristics between the two groups of patients (Table 1) .
The efficacy results (Tables 2 and 3) show that pain on active movement, pain at rest and judgement of disease activity improved significantly both in patients treated with AMG and in those treated with piroxicam (P < 0.01); there was no significant difference between the two groups.
Overall assessments of the efficacy of the treatments, both by the patient and the physician, were similar in the two groups and there were no statistically significant differences.
Both the patients' and physicians' assessments of tolerability were better in the AMG group, a statistically significant difference in the case of the patient assessment (P < 0.05) but not the physician assessment (Table 4 ).
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group and nine of 50 in the piroxicam group (Table 5) , a statistically significant difference (P < 0.05). Serious gastrointestinal sideeffects occurred only in patients treated with piroxicam: one case of a bleeding gastric ulcer, one case of haematemesis from severe and diffuse haemorrhagic gastritis, one case of melaena from a bleeding bulbar ulcer. The loss of blood in the two patients with peptic ulcer necessitated blood transfusion. The total number of side-effects, however, was similar in the two groups (20 patients in the AMG group and 18 in the piroxicam group). Table 6 gives details of the side-effects reported.
No statistically significant changes in the laboratory analyses were observed in the AMG group, whereas in the piroxicam group statistically significant reductions in haemoglobin ( P = 0.005), in the haematocrit value (P = 0.015), and in the number of red corpuscles (P = 0.005) were observed. These laboratory values remained within the normal ranges, however, and the differences between the treatment groups were only significant for the red blood cells.
DISCUSSION
Our study showed that in the symptomatic treatment of arthritis, AMG is similar in efficacy to piroxicam -one of the most widely used NSAIDs in Europe, known for its efficacy and good tolerability profile. 19 Patients treated with this new NSAID not only experienced a reduction in arthritic pain both during rest and activity, but also reported a reduction in the activity of the disease, and therefore considered the therapy to be effective, as did the patients treated with piroxicam.
The majority of trials comparing NSAIDs in osteoarthritis do not show significant differences, whereas 89% of placebocontrolled trials do show such differences. 20 As we expected, in the present case we found no difference between the effectiveness of AMG and piroxicam, but the 
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greater tolerability of AMG was evident. The number of patients with side-effects was the same in both groups, but the nature and severity of these side-effects differed. There were nine of 50 (18%) withdrawals because of side-effects in the piroxicam group, significantly more than the two of 49 (4%) in the AMG group, and all the withdrawals in the piroxicam group were the result of gastrointestinal toxicity. Three patients treated with piroxicam had serious complications: bleeding ulcer, melaena and haematemesis, and seven complained of epigastric pain (in four cases the intensity led to their withdrawal) and three of abdominal pain.
Thus in the present study, the incidence of serious gastrointestinal side-effects was 6% with piroxicam, an extremely high value when compared with trials conducted on large numbers. 21 -23 Further, osteoarthritic patients, such as ours, generally show a 
lower incidence of side-effects from NSAIDs than do rheumatoid arthritis patients. 24 Our small sample does not, however, allow us to draw firm conclusions on this point. In the patients treated with AMG, we found only three cases of epigastralgic pain, all of them mild, and no cases of perforation, ulceration or bleeding (PUB); the only two withdrawals in this group were caused by headache and nausea. The patients' assessment of tolerability was also significantly better for AMG than for piroxicam.
The relative gastric safety of amtolmetin guacyl in the present study is consistent with the results of a recent clinical and endoscopic trial on patients suffering from rheumatoid arthritis, which documented the appearance of ulcer in 3% of patients treated with AMG compared with 25% of patients treated with diclofenac. 18 
It is well known that the gastric lesions caused by NSAIDs are mainly due to their inhibition of prostaglandin by blocking cyclo-oxygenase (COX). It is now commonly believed that the best-tolerated NSAIDs are those that inhibit mainly COX-2, which is induced by inflammatory stimuli, sparing COX-1, which is a constitutive, physiological form. 6, 24 -26 AMG inhibits both COX-1 and COX-2 and, therefore, cannot be considered a selective antagonist of COX-2; in effect, its active metabolite is tolmetin, an old NSAID with a good record of effectiveness and toxicity. 27 Despite this, AMG seems almost devoid of toxic gastric properties, as confirmed by our results, possibly thanks to its individual characteristics.
In animal experiments, AMG administered intragastrically was devoid of gastric effects, whereas its metabolite tolmetin, administered in the same way, caused gastric lesions. 17 AMG does not modify the basal gastric potential difference, unlike aspirin and ibuprofen, and it reduces the drop in the potential difference induced by ethanol. 16 These effects seem to depend on the fact that AMG induces an increase in NO synthase type-2 activity, whereas its metabolites are inactive. NO is recognized as a fundamental mediator of gastric mucosal defense, and a promising new therapeutic approach is to associate NO with NSAIDs (NO-NSAIDs). 28, 29 Unlike NO-NSAIDs, which release NO into the systemic circulation, AMG generates NO only in the gastrointestinal tract, where the molecule arrives intact, being rapidly hydrolysed by plasma esterases as soon as it enters the circulation.
Significant reductions in haemoglobin, haematocrit values and red blood cells were observed in patients treated with piroxicam. Although the variations of the average values were modest and within the normal range, it is probable that these reductions reflect the major gastric effects of piroxicam, especially in view of the three cases of PUB that appeared in this group. 
In conclusion, our study seems to confirm the effectiveness and tolerability of AMG 
